Date: 2017-11-09
Type of information: Construction of new premises
Compound: cGMP manufacturing facility, new headquarters
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On November 9, 2017, Sangamo Therapeutics announced a strategic investment in manufacturing, including an expanded commitment with Brammer Bio, plans to build a proprietary cGMP manufacturing facility in the new Sangamo corporate headquarters in Brisbane, California.
- Sangamo's strategic investment in large scale manufacturing capacity and capabilities represents a balanced approach to meet the needs of its rapidly expanding pipeline of genomic therapy product candidates. The expanded services agreement with Brammer Bio will provide Sangamo dedicated capacity for clinical supply of the Company's lead development programs and builds on a strong, decade-long relationship between the two companies.
- Sangamo is also planning to build a state-of-the-art cGMP manufacturing facility that will initially be focused on product development and Phase 1/2 clinical trial supply for new pipeline programs. This facility will be located on-site at Sangamo's planned new headquarters.
- The new corporate headquarters at 7000 Marina Boulevard, are an 88,000 square foot building at Oyster Point in Brisbane, California, in the heart of the biotech hub south of San Francisco. Occupancy of the Brisbane site is expected in late 2018, after completion of architectural improvements. The company will retain its Point Richmond location as a Sangamo Research Center.
Financial terms:
Latest news:
Is general: Yes
